Skip to content

COMPANY
- OVERVIEW
- LEADERSHIP
- BOARD
- INVESTORS
- TIMELINE
OUR SCIENCE
PIPELINE
NEWS & EVENTS
TEAM & CAREERS
LEGAL NOTICE
DISCLAIMER
DATA PROTECTION
HOME

BIO-Europe 2026

Meet us in Cologne, Germany, November 9 – 11, 2026

https://informaconnect.com/bioeurope/

Post navigation

OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)

OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA

OMEICOS Therapeutics GmbH
Robert-Rössle-Strasse 10 (Building 79)
13125 Berlin, Germany
t +49 (0)30 9489 4810
f +49 (0)30 9489 4811
info@omeicos.com

OMEICOS Therapeutics, Inc.
c/o Remiges Biopharma Fund GP, Inc.
One Broadway, 14th Floor,
Cambridge, MA 02142, USA
info@omeicos.com

LEGAL NOTICE
DISCLAIMER
DATA PROTECTION

FOLLOW US

© 2026 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.